부산대학교 도서관

Introduction: Cardiac involvement is common and may become clinically relevant in approximately 5%–10% of patients with systemic sarcoidosis. Although reduced left ventricular ejection fraction is a recognized predictor of mortality, recent studies have suggested an increased risk of ventricular arrhythmia (VAs) and sudden cardiac death (SCD) in patients with cardiac sarcoidosis (CS) and evidence of late gadolinium enhancement‐cardiac magnetic resonance (LGE‐CMR), irrespective of the underlying left ventricular systolic function. We performed a meta‐analysis to assess the correlation between VAs/SCD and presence of LGE‐CMR in CS patients. Methods: We systematically searched Medline, Embase, and Cochrane electronic databases up to January 2, 2023, for studies enrolling patients with suspected or confirmed CS undergoing LGE‐CMR. Clinical outcomes of interest included clinically relevant VAs, defined as sustained ventricular tachycardia, ventricular fibrillation, SCD, or aborted SCD during follow‐up. The effect size was estimated using a random‐effect model as risk ratio (RR) and relative 95% confidence interval (CI). Results: A total of 14 studies fulfilled the selection criteria and were included in the final analysis. Among 1273 patients, LGE was detected in 465 (36.5%; Group LGE+). Males accounted for 45.2% (95% CI: 40.5%–55.7%) of the total population and the average age was 56.8 (95% CI: 52.7%–60.9) years. A total of 104 (22.3%) of 465 LGE+ patients experienced a clinically relevant VA, compared to 6 (0.7%) of 808 LGE‐ ones. LGE+ was associated with a ninefold increased risk in life‐threatening VAs (22.3% vs. 0.7%; RR = 9.52; 95% CI [5.18–17.49]; p <.0001) compared to patients without LGE (heterogeneity I2 = 0%). Conclusion: In our meta‐analysis, LGE+ in patients with CS was associated with a ninefold increased risk in life‐threatening VAs compared to patients without LGE. [ABSTRACT FROM AUTHOR]